Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating eye diseases and composition of medicine

A composition and ophthalmic disease technology, applied in the fields of biochemistry and protein engineering, can solve the problems of toxic side effects, mediocre clinical effect, and difficulty in industrial production

Active Publication Date: 2017-05-24
BEIJING NORTHLAND BIOTECH
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its disadvantage is that the purity of chemical synthesis is low, and it contains organic impurities and inorganic impurities with similar structures, which will produce toxic and side effects
At the same time, chemically synthesized thymosin β4 is clinically used in large doses, and the clinical effect is average.
At the same time, the yield of chemically synthesized peptides is low, and industrial production is difficult, which cannot meet the needs of clinical use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating eye diseases and composition of medicine
  • Medicine for treating eye diseases and composition of medicine
  • Medicine for treating eye diseases and composition of medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 Determination of the influence of rh Tβ4 on MUC5AC and MUC1 mRNA gene expression by RT-PCR

[0023] Drug source: The natural β4 in this experiment was obtained by chemical synthesis, and the recombinant human thymosin β4 was provided by Beijing Northland Biotechnology Co., Ltd., respectively Gly-rh Tβ4 and Ala-rh Tβ4, two for each sample specifications (50, 100μg / mL).

[0024] Conjunctival cells were isolated from donated eyeballs from eye banks, and conjunctival goblet cells were cultured and purified in vitro. Different thymosin β4 (Gly-rh Tβ4 50 μg / mL, Gly-rh Tβ4 100 μg / mL, Ala-rh Tβ4 50μg / mL, Ala-rh Tβ4 100μg / mL), natural Tβ4 is chemically synthesized Tβ4 (0.1% or 1mg / mL, as a positive control), and the negative control group (negative control) was given PBS. The effect of thymosin β4 on mucin expression-related genes MUC5AC and MUC1 mRNA was determined by RT-PCR and Western blot.

[0025] The results of in vitro experiments showed that: rh-Tß4 can promo...

Embodiment 2

[0029] Example 2 rh-Tβ4 on the rat dry eye model corneal fluorescein sodium scoring results

[0030] Rat dry eye model prepared with 0.3% benzalkonium chloride, dry eye animals were randomly divided into 6 groups, 6 animals in each group, and were given rh-Tβ4 (Gly-rh Tβ4 50μg / mL, Gly-rh Tβ4 100μg / mL, Ala-rh Tβ4 50μg / mL, Ala-rh Tβ4 100μg / mL), natural Tβ4 (0.1% or 1mg / mL, positive control group) and PBS (negative control group), drop three times a day, continuous Administration for 7 days. Observe the corneal fluorescein sodium score of rh-Tβ4. The results showed that the rh-Tß4 and positive control group had a downward trend compared with the negative control group, and the Gly-rh Tβ4 100µg / mL dose group and the Ala-rh Tβ4 100µg / mL dose group were significantly different from the negative control group (p< 0.05). Ala-rh Tβ4 100µg / mL dose group, Gly-rh Tβ4 50µg / mL dose group and Gly-rh Tβ4 100µg / mL dose group were compared with the positive control group, and the results we...

Embodiment 3

[0034] Example 3 Slit lamp anterior segment photography and fluorescein sodium staining scoring results of rh-Tβ4 on rat dry eye model after treatment

[0035] Rat dry eye model prepared with 0.3% benzalkonium chloride, dry eye animals were randomly divided into 6 groups, 6 animals in each group, respectively given different rh-Tβ4 (Gly-rh Tβ4 50μg / mL, Gly-rh Tβ4 100μg / mL, Ala-rh Tβ4 50μg / mL, Ala-rh Tβ4 100μg / mL), natural Tβ4 (0.1% or 1mg / mL, positive control group) and PBS (negative control group), drop three times a day , Continuous administration for 7 days. see results figure 1. The results of sodium fluorescein staining showed that the Gly-rh Tβ4 100µg / mL dose group and the Ala-rh Tβ4 100µg / mL dose group had the most obvious corneal repair effect, which was significantly different from the positive control drug, and the Gly-rh Tβ4 50µg / mL dose group It was basically the same as the positive control group, but there was no significant difference between Ala-rh Tβ4 50µg / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides application of a pharmaceutical composition containing recombinant human prothymosin beta4 in preparation of a medicine for treating eye diseases and particularly application in the treatment of xerophthalmia. The pharmaceutical composition is characterized in that the concentration of the recombinant human prothymosin beta4 is 1ug / mL-1000ug / mL. The invention further provides the pharmaceutical composition containing pharmaceutically acceptable carriers.

Description

technical field [0001] The invention relates to the technical fields of biochemistry and protein engineering, in particular to a medicine capable of treating dry eye syndrome and a composition thereof. Background technique [0002] Dry eye syndrome refers to the general term for various diseases caused by abnormal tear quality or quantity or dynamics caused by any reason, resulting in decreased tear film stability, accompanied by ocular discomfort and (or) ocular surface tissue lesions. Also known as keratoconjunctival sicca. Common symptoms include dry eyes, easy fatigue, itchy eyes, foreign body sensation, burning pain, sticky secretions, fear of wind, photophobia, and sensitivity to external stimuli; Tears are secreted, resulting in frequent tearing; in severe cases, the eyes will appear red, swollen, hyperemic, and keratinized, and the corneal epithelium will peel off and there will be filaments attached. This kind of damage can cause keratoconjunctival lesions over tim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/22A61P27/02
CPCA61K38/2292
Inventor 马素永许松山聂李亚徐立华马杉姗汤晓闯徐宏伟
Owner BEIJING NORTHLAND BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com